Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that topical finasteride may benefit women with facial hirsutism, based on observations from a small sample.

This study presents a case where a young male with cryptogenic stroke and patent foramen ovale, using finasteride, experienced symptomatic improvement after PFO closure and discontinuing finasteride, suggesting cardiovascular risks associated with the drug.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This case report describes a 15-year-old female whose initial systemic lupus erythematosus manifestations were fever and rash appearing separately, illustrating diagnostic challenges between SLE and infection.

This study found that finasteride treatment reduced urinary androgen and prostaglandin levels in male pattern baldness patients to levels similar to healthy controls.

This meta-analysis found that patients with androgenetic alopecia have an atherogenic lipid profile, with higher LDL, triglycerides, and total cholesterol, and lower HDL, potentially explaining increased cardiovascular risk.

Finasteride and dutasteride increase sexual dysfunction reports.

In this study, finasteride was found to potentiate stress-induced disruption in sensory gating of rats by neutralizing the increase in allopregnanolone levels after acute stress.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This study found that finasteride gel 0.25% significantly decreased hair growth in women with idiopathic hirsutism over six months without any reported side effects.

In this study, repeated finasteride administration was associated with decreased social interaction and cognitive deficits in male rats, potentially linked to changes in cholinergic system activity.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

This study found that acute finasteride treatment decreased ethanol intake in male C57BL/6J mice, whereas chronic treatment showed diminished effects, implying compensatory changes in neurosteroid modulation.

In this preliminary study, women with facial hirsutism treated with topically applied finasteride cream showed a significant decrease in hair growth and thickness compared to placebo, without adverse effects.

Finasteride reduces inflammation and improves immune response after trauma by altering hormone levels.

This study found that invasomes enhanced the iontophoretic transdermal delivery of finasteride in rabbits, increasing AUC and T1/2 compared to oral suspension.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This research found that liquid-state liposomes and niosomes may enhance finasteride delivery to pilosebaceous units in hamsters more effectively than gel-state vesicles or hydroalcoholic solution.

This preliminary study suggests that finasteride might cause depressive symptoms, indicating the need for cautious prescription in patients at high risk for depression.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that oral finasteride, at a dosage of 2.5 mg/day or more, may improve hair growth and appearance in postmenopausal women with pattern hair loss, without adverse effects.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.

This study found that finasteride may decrease and control the frequency of priapism episodes in patients with sickle cell anemia, with fewer side effects compared to other treatments.

This study found that finasteride treatment improved cardiac function and reduced heart failure progression in mice, suggesting it could be a potential therapy for pathological cardiac hypertrophy and dysfunction.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.